title: Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
abstract: We report here the successful treatment of hepatitis C virus (HCV) transmitted from a nucleic acid testing (NAT)-negative donor to three HCV-negative recipients-two renal transplants and one liver. Both renal recipients underwent standard deceased-donor renal transplantation with immediate graft function. The liver recipient underwent standard orthotopic liver transplantation and recovered uneventfully. The donor was a 39-year-old woman with a terminal serum creatinine of 0.7 mg/dL. She was high risk for bloodborne pathogens, based upon a history of sexual contact with an HCV-infected male partner. Recipient 1 was a 45-year-old man with a history of end-stage renal disease from systemic lupus erythematosus. Recipient 2 was a 62-year-old woman with a history of end-stage renal disease caused by hypertension and insulin-dependent diabetes. Recipient 3 was a 42-year-old man with acute liver failure from acetaminophen ingestion. All recipients became HCV polymerase chain reaction positive on post-transplant follow-up. Both kidney recipients were treated with ledipasvir/sofosbuvir combination therapy for 12 weeks without side effects or rejection episodes. Recipient 3 was treated with ledipasvir/sofosbuvir in combination with ribavirin for 12 weeks without side effects. All patients achieved a sustained viral response at 12 weeks and are considered cured of HCV. The kidney recipients maintained good allograft function with a serum creatinine of 1.4 mg/dL and 1.0 mg/dL, respectively. Both renal recipients maintained normal liver function post treatment and did not develop any evidence of fibrosis. The liver recipient's liver function tests returned to normal without further incident. This case report provides evidence for the successful treatment of donor-derived HCV in transplant recipients.
authors.affiliation: Transplant Division, Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA.
authors.forename: Ashesh P
authors.initials: AP
authors.lastname: Shah
authors.affiliation: Department of Surgery, Johns Hopkins University, Baltimore, MD, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Cameron
authors.affiliation: Division of Nephrology, Thomas Jefferson University, Philadelphia, PA, USA.
authors.forename: Pooja
authors.identifier: http://orcid.org/0000-0002-0253-2970
authors.initials: P
authors.lastname: Singh
authors.affiliation: Transplant Division, Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA.
authors.forename: Adam M
authors.initials: AM
authors.lastname: Frank
authors.affiliation: Division of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia, PA, USA.
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Fenkel
mesh_terms: D000082:Acetaminophen / Q000633:toxicity; D000328:Adult; D064591:Allografts / Q000821:virology*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017848:Blood-Borne Pathogens / Q000302:isolation & purification*; D056486:Chemical and Drug Induced Liver Injury / Q000601:surgery; D018562:Disease Transmission, Infectious; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D005449:Fluorenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016174:Hepacivirus / Q000302:isolation & purification*; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000009:adverse effects*; D016031:Liver Transplantation / Q000009:adverse effects* / Q000379:methods; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000302:isolation & purification; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000069474:Sofosbuvir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D066027:Transplant Recipients; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D001562:Benzimidazoles; D005449:Fluorenes; D012367:RNA, Viral; C586541:ledipasvir; D000082:Acetaminophen; D012254:Ribavirin; D000069474:Sofosbuvir
keywords: 
  DAA
  ; 
  HCV
  ; PHS increased risk; donor-derived infections